Meeting
2016 ASCO Annual Meeting
MKNK1 SNP rs8602 to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.
Authors
Martin D. Berger
Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, CA
Martin D. Berger , Sebastian Stintzing , Volker Heinemann , Dongyun Yang , Yu Sunakawa , Yan Ning , Satoshi Matsusaka , Satoshi Okazaki , Yuji Miyamoto , Mitsukuni Suenaga , Marta Schirripa , Jordan David West , Diana L. Hanna , Afsaneh Barzi , Wu Zhang , Heinz-Josef Lenz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Tumor-Based Biomarkers
Citation
J Clin Oncol 34, 2016 (suppl; abstr 11588)
DOI
10.1200/JCO.2016.34.15_suppl.11588
Abstract #
11588
Poster Bd #
285
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Polymorphisms of genes encoding for vitamin D binding protein and Wnt5a to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.
First Author: Martin D. Berger
Poster
2017 Gastrointestinal Cancers Symposium
Effect of JAK2 SNP rs2274472 on outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.
First Author: Martin D. Berger
Poster
2016 ASCO Annual Meeting
Genetic variants of R-spondin genes to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and bevacizumab (FOLFIRI/BEV) in FIRE-3 cohort.
First Author: Yan Ning
Poster
2021 Gastrointestinal Cancers Symposium
Single nucleotide polymorphisms (SNPs) in endoplasmic reticulum (ER) stress response genes to predict first-line treatment outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from the MAVERICC and FIRE-3 trials.
First Author: Francesca Battaglin